BACKGROUND: Men who have sex with men (MSM) are at high risk for hepatitis B virus (HBV) infection. Data on the effect of highly active antiretroviral therapy (HAART) on incident HBV infection in HIV-infected and HIV-uninfected MSM are limited. OBJECTIVE: To determine predictors of incident HBV infection in MSM during pre-HAART and HAART periods. DESIGN: Observational cohort study. SETTING: Cohort of MSM who have, or are at risk for, HIV infection. PATIENTS: 2375 HBV-uninfected MSM in the Multicenter AIDS Cohort Study. MEASUREMENTS: Poisson regression was used to compare incidence rates of HBV infection in the pre-HAART and HAART eras and to identify factors associated with incidence of HBV infection. RESULTS: In 25,322 person-years of follow-up, 244 incident HBV infections occurred. The unadjusted incidence rate was higher in HIV-infected MSM than in HIV-uninfected MSM (incidence rate ratio [IRR], 1.9 [95% CI, 1.5 to 2.4]) and was significantly lower in the HAART era than in the pre-HAART era among HIV-infected (IRR, 0.2 [CI, 0.1 to 0.4]) and HIV-uninfected (IRR, 0.3 [CI, 0.2 to 0.4]) MSM. Age younger than 40 years (IRR, 2.3 [CI, 1.7 to 3.0]), more than 1 recent sexual partner (IRR, 3.1 [CI, 2.3 to 4.2]), and HIV infection (IRR, 2.4 [CI, 1.8 to 3.1]) were independently associated with higher incidence of HBV infection, whereas HBV vaccination was protective (IRR, 0.3 [CI, 0.2 to 0.4]). Highly active antiretroviral therapy with HIV RNA levels less than 400 copies/mL was associated with protection (IRR, 0.2 [CI, 0.1 to 0.5]), but HAART in those with HIV RNA levels of 400 copies/mL or greater was not. LIMITATION: The observational nature limits inferences about causality. CONCLUSION: Effective HAART is associated with lower incidence of HBV infection; however, even in the HAART era, incidence of HBV infection remains high among MSM. PRIMARY FUNDING SOURCE: National Institute of Allergy and Infectious Diseases.
BACKGROUND:Men who have sex with men (MSM) are at high risk for hepatitis B virus (HBV) infection. Data on the effect of highly active antiretroviral therapy (HAART) on incident HBV infection in HIV-infected and HIV-uninfected MSM are limited. OBJECTIVE: To determine predictors of incident HBV infection in MSM during pre-HAART and HAART periods. DESIGN: Observational cohort study. SETTING: Cohort of MSM who have, or are at risk for, HIV infection. PATIENTS: 2375 HBV-uninfected MSM in the Multicenter AIDS Cohort Study. MEASUREMENTS: Poisson regression was used to compare incidence rates of HBV infection in the pre-HAART and HAART eras and to identify factors associated with incidence of HBV infection. RESULTS: In 25,322 person-years of follow-up, 244 incident HBV infections occurred. The unadjusted incidence rate was higher in HIV-infected MSM than in HIV-uninfected MSM (incidence rate ratio [IRR], 1.9 [95% CI, 1.5 to 2.4]) and was significantly lower in the HAART era than in the pre-HAART era among HIV-infected (IRR, 0.2 [CI, 0.1 to 0.4]) and HIV-uninfected (IRR, 0.3 [CI, 0.2 to 0.4]) MSM. Age younger than 40 years (IRR, 2.3 [CI, 1.7 to 3.0]), more than 1 recent sexual partner (IRR, 3.1 [CI, 2.3 to 4.2]), and HIV infection (IRR, 2.4 [CI, 1.8 to 3.1]) were independently associated with higher incidence of HBV infection, whereas HBV vaccination was protective (IRR, 0.3 [CI, 0.2 to 0.4]). Highly active antiretroviral therapy with HIV RNA levels less than 400 copies/mL was associated with protection (IRR, 0.2 [CI, 0.1 to 0.5]), but HAART in those with HIV RNA levels of 400 copies/mL or greater was not. LIMITATION: The observational nature limits inferences about causality. CONCLUSION: Effective HAART is associated with lower incidence of HBV infection; however, even in the HAART era, incidence of HBV infection remains high among MSM. PRIMARY FUNDING SOURCE: National Institute of Allergy and Infectious Diseases.
Authors: Sanny Y Chen; Steven Gibson; Mitchell H Katz; Jeffrey D Klausner; James W Dilley; Sandra K Schwarcz; Timothy A Kellogg; Willi McFarland Journal: Am J Public Health Date: 2002-09 Impact factor: 9.308
Authors: Masaaki Miyazawa; Lucia Lopalco; Francesco Mazzotta; Sergio Lo Caputo; Francisco Veas; Mario Clerici Journal: AIDS Date: 2009-01-14 Impact factor: 4.177
Authors: R Detels; L Jacobson; J Margolick; O Martinez-Maza; A Muñoz; J Phair; C Rinaldo; S Wolinsky Journal: Public Health Date: 2011-12-27 Impact factor: 2.427
Authors: Karen W Hoover; Mary Butler; Kimberly A Workowski; Stephen Follansbee; Beau Gratzer; C Bradley Hare; Barbara Johnston; John L Theodore; Guoyu Tao; Bryce D Smith; Terence Chorba; Charlotte K Kent Journal: Sex Transm Dis Date: 2012-05 Impact factor: 2.830
Authors: Cindy M Weinbaum; Rob Lyerla; Duncan A Mackellar; Linda A Valleroy; Gina M Secura; Stephanie K Behel; Trista Bingham; David D Celentano; Beryl A Koblin; Marlene Lalota; Douglas A Shehan; Hanne Thiede; Lucia V Torian Journal: Am J Public Health Date: 2008-04-01 Impact factor: 9.308
Authors: Helen M Chun; Ann M Fieberg; Katherine Huppler Hullsiek; Alan R Lifson; Nancy F Crum-Cianflone; Amy C Weintrob; Anuradha Ganesan; Robert V Barthel; William P Bradley; Brian K Agan; Michael L Landrum Journal: Clin Infect Dis Date: 2010-02-01 Impact factor: 9.079
Authors: Robert C Bollinger; Chloe L Thio; Mark S Sulkowski; Jane McKenzie-White; David L Thomas; Charles Flexner Journal: Lancet HIV Date: 2019-12-20 Impact factor: 12.767
Authors: Emmanuel Seremba; Victor Ssempijja; Sarah Kalibbala; Ronald H Gray; Maria J Wawer; Fred Nalugoda; Corey Casper; Warren Phipps; Ponsiano Ocama; David Serwadda; David L Thomas; Steven J Reynolds Journal: AIDS Date: 2017-03-27 Impact factor: 4.177
Authors: Jefferson M Jones; Brian M Gurbaxani; Alice Asher; Stephanie Sansom; Pallavi Annambhotla; Anne C Moorman; Saleem Kamili; John T Brooks; Sridhar V Basavaraju Journal: Am J Transplant Date: 2019-05-10 Impact factor: 8.086
Authors: Oluwaseun Falade-Nwulia; Eric C Seaberg; Anna E Snider; Charles R Rinaldo; Steven M Wolinsky; Mallory D Witt; Chloe L Thio Journal: AIDS Date: 2021-05-01 Impact factor: 4.632
Authors: Elizabeth Wahome; Caroline Ngetsa; John Mwambi; Huub C Gelderblom; Gloria Omosa Manyonyi; Murugi Micheni; Amin Hassan; Matt A Price; Susan M Graham; Eduard J Sanders Journal: Open Forum Infect Dis Date: 2016-12-07 Impact factor: 3.835
Authors: Olusegun A Adeyemi; Andrew Mitchell; Ashley Shutt; Trevor A Crowell; Nicaise Ndembi; Afoke Kokogho; Habib O Ramadhani; Merlin L Robb; Stefan D Baral; Julie A Ake; Manhattan E Charurat; Sheila Peel; Rebecca G Nowak Journal: BMC Infect Dis Date: 2021-07-06 Impact factor: 3.090
Authors: Adam Abdullahi; Olga Mafotsing Fopoussi; Judith Torimiro; Mark Atkins; Charles Kouanfack; Anna Maria Geretti Journal: Open Forum Infect Dis Date: 2018-10-05 Impact factor: 3.835